A European and Canadian multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Ad5FGF-4 in patients with stable angina

×

Message d'erreur

  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 53 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 95 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
A European and Canadian multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Ad5FGF-4 in patients with stable angina
Date receipt dossier: 
11 juil 2002
Pharmaceutical study code: 
305602
Company / Sponsor: 
Schering N.V./S.A.
Phase: 
IIb/III
Treated organism: 
Humans
Indication category: 
Cardiovascular therapy
Disease: 
Chronic angina pectoris
Therapeutic approach: 
Gene therapy
Genetic modification: 
human FGF-4
Method of transfer of nucleic acid of interest: 
Human Adenovirus serotype 5
Administered biological material: 
Recombinant Adenovirus D (E1A, E1B)
Route of administration: 
Intracoronary
Locations in Belgium: 
Universitair Ziekenhuis Gasthuisberg, Leuven - O.-L.-Vrouwziekenhuis, Aalst
Type of procedure: 
Contained use only
Current status: 
Authorized